RxDoctor Payments Data

Cassilyn Lambert

Gerontology · Newburgh, INNPI 1669043030

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 102 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,234 and has fallen 54.9% since, to $556 in 2024.

$2,228in general payments, 2019–2025

Across 102 payments — averaging $21.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$413
  • AbbVie$377
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$223
  • Regeneron Healthcare Solutions, Inc.$211
  • Takeda Pharmaceuticals U.S.A., Inc.$184
  • Sanofi$109
  • plus $710 from 16 others

What the payments were for

  • Food & beverage$2,228100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,228 in reported general payments places this provider in the 80th percentile of 230 gerontology providers in Indiana.

See all gerontology providers in Indiana

Medicare billing

Part B allowed, 2024
$37,090
Medicare patients
184
Services billed
984

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin11$33,674
LinzessLinaclotide13$9,708
Pantoprazole Sodium62$908
Omeprazole25$462

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$223$33,67411 claims
AbbVieLinzess$377$9,70813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 230 gerontology providers in Indiana.

Other gerontology in Newburgh

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →